|
|
"A comprehensive, collaborative elections resource."
|
At F.D.A., Strong Drug Ties and Less Monitoring
|
|---|
| Parent(s) |
Issue
|
| Contributor | RP |
| Last Edited | RP Dec 07, 2004 02:37pm |
| Logged |
0
|
| Category | Analysis |
| Media | Newspaper - New York Times |
| News Date | Monday, December 6, 2004 06:00:00 AM UTC0:0 |
| Description | When federal drug officials suspected in 1992 that a popular allergy pill might cause heart problems, they turned to their own scientists. Their trial confirmed the danger, and the drug was pulled from the market.
Eight years later, similar worries surrounded the arthritis pill Vioxx. But by then, the Food and Drug Administration had shifted gears, slashing its laboratories and network of independent drug safety experts in favor of hiring more people to approve drugs, changes that arose under an unusual agreement that has left the agency increasingly reliant on and bound by drug company money. Discovering Vioxx's dangers would take four more years.
That delay has led to a firestorm of criticism. Members of Congress, an internal F.D.A. whistleblower and prominent medical journals have said the agency is incapable of uncovering the perils of drugs that have been approved and are in wide distribution. Some have accused it of being cozy with drug makers. |
| Share |
|
|
2¢
|
|
| Article | Read Full Article |
|
| Date |
Category |
Headline |
Article |
Contributor |
|
|
